Drug Profile
Kukoamine B
Alternative Names: C 17616; KB; kukoamine B mesilateLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Tianjin Chase Sun Pharmaceutical
- Class Alkaloids; Antiseptics; Biogenic amines; Caffeic acids; Polyamines; Small molecules
- Mechanism of Action Bacterial DNA inhibitors; Lipopolysaccharide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Sepsis
Most Recent Events
- 15 May 2021 Phase-II clinical trials in Sepsis in China (IV) (NCT04803955)
- 18 Mar 2021 Tianjin Chasesun Pharmaceutical plans a HR-KB201 phase II trial for Bacterial infections and Sepsis (In adults; In the elderly) in China (IV) in May 2021 (NCT04803955)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Sepsis in China (IV)